Clinical Trial on the Mixture of G, C and S in Treatment of Patients With RCC (SOGUG-02-06)

This study has been completed.
Sponsor:
Information provided by:
Spanish Oncology Genito-Urinary Group
ClinicalTrials.gov Identifier:
NCT00496301
First received: July 3, 2007
Last updated: January 13, 2009
Last verified: January 2009

July 3, 2007
January 13, 2009
November 2006
April 2008   (final data collection date for primary outcome measure)
Progression-free survival [ Time Frame: every 3 cycles and every two months in patients with "sorafenib" administered as monotherapy ] [ Designated as safety issue: No ]
Main: progression-free survival. Secondary: Security profile, Objective response index (RC/RP) and tumour growth (RC/RP/EE), Duration of response, Global survival, Time to progression [ Time Frame: every 3 cycles and every two months in patients with "Sorafenib" adminitered as monotherapy ]
Complete list of historical versions of study NCT00496301 on ClinicalTrials.gov Archive Site
  • security profile [ Time Frame: every 3 cycles and every two months in patients with "sorafenib" administered as monotherapy ] [ Designated as safety issue: Yes ]
  • Objective response index (CR/PR) and tumor growth control (CR/PR/SD) [ Time Frame: every three cycles and every two months in patients with "Sorafenib" treated as single agent ] [ Designated as safety issue: No ]
  • Duration of response [ Time Frame: every three cycles and every two months in patients with "Sorafenib" treated as single agent ] [ Designated as safety issue: No ]
  • Global survival [ Time Frame: At last contact date or death date ] [ Designated as safety issue: No ]
  • Time to progression [ Time Frame: every three cycles and every two months in patients with "Sorafenib" treated as single agent ] [ Designated as safety issue: No ]
Not Provided
Not Provided
Not Provided
 
Clinical Trial on the Mixture of G, C and S in Treatment of Patients With RCC
Phase II Clinical Trial, Non-Randomized, Multicentre, on the Combination of Gemcitabine, Capecitabine and Sorafenib (Bay 43-9006) in Treatment of Patients With Unresectable and/or Metastatic Renal Cell Carcinoma (RCC)

Main Objective:

To evaluate progression-free survival in patients with unresectable renal cell carcinoma (RCC) treated with a combination of gemcitabine, capecitabine, and sorafenib.

Not Provided
Interventional
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Carcinoma, Renal Cell
Drug: Gemcitabine, Capecitabine and Sorafenib (6 cycles)
Gemcitabine: 1000 mg/m2 i.v. days 1 and 8. Capecitabine: 650 mg/m2 i.v. day 1 to 14. (change to 500mg/m2 after amendment nº2 (dated on 10/10/2007) Sorafenib:400 mg/12h v.o. day 1 to 21
Other Names:
  • Gemzar
  • Xeloda
  • Nexavar
Not Provided
Bellmunt J, Trigo JM, Calvo E, Carles J, Pérez-Gracia JL, Rubió J, Virizuela JA, López R, Lázaro M, Albanell J. Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06). Lancet Oncol. 2010 Apr;11(4):350-7. doi: 10.1016/S1470-2045(09)70383-3. Epub 2010 Feb 15.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
40
December 2008
April 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients must give their written informed consent before any procedure related to the study is performed; therefore, it must be given at the selection visit. The patient must be informed that he has the right to withdraw from the study at any time, without any kind of prejudice.
  • Patients with renal clear cell carcinoma (RCC), unresectable and/or metastatic, histologically or cytologically documented (excluding the less common subtypes).
  • Patients must not be candidates for any immunotherapeutic treatment, according to the response predictive factors, or must be intolerant to immunotherapeutic treatment.
  • Patients classified as having median or low risk, according to Motzer's scoring.
  • Patients (men or women) with ages equal or superior to 18 years old.
  • ECOG ≤ 1.
  • Assessable or measurable disease.
  • Patients with adequate haematological function, defined as:

    • Neutrophils ≥ 1.5 x 10^9/L
    • Blood platelets ≥ 100 x 10^9/L
    • Haemoglobin ≥ 10 g/dl
  • Patients with adequate hepatic, renal, medullar and coagulation function, according to the following criteria:

    • Total bilirubin < 1.5 times the superior limit of normality
    • ALT and AST < 2.5 times the superior limit of normality (< 5 times the superior limit of normality in case of liver failure due to cancer)
    • Amylase and lipase < 1.5 times the superior limit of normality
    • Serum creatinine < 2 times the superior limit of normality
    • TP or INR and TTP < 1.5 times the superior limit of normality. If patient is receiving anticoagulants, strict monitoring will be carried out, with evaluations on a weekly basis, at least, until the INR is stable, referring to a determination previous to dose administration, according to local standard care.
  • Patients with a life expectancy superior to 12 weeks, at least.
  • Patients may have received radiotherapy; however, this must not be the only target lesion.
  • Patients from both sexes must use adequate contraceptive methods (oral or injectable contraceptives, intrauterine device, condom, sterilization) whilst participating in the protocol. After the retreat of treatment with BAY 43-9006, the contraceptive methods must be used for 4 weeks in women and for 3 months in men.
  • Patients who are capable of accomplishing the study's requirements and without any impediments to follow the instructions while on study

Exclusion Criteria:

  • Patients who do not give their written informed consent to participate in the study.
  • Patients with less common RCC subtypes, such as pure papillary cell tumours, Bellini carcinoma, medullary carcinoma or the oncocytic chromophobes and sarcomatoid variants, will be excluded from the study.
  • Patients that have received previous treatment with chemotherapy or that had tumours that evolved during or after immunotherapy treatment.
  • Patients that, due to their characteristics, may obtain a potential benefit from immunotherapy treatment.
  • Patients that have received previous anti-angiogenic treatment.
  • High-risk patients according to Motzer's classification.
  • Concomitant treatment with another chemotherapy or immunotherapy.
  • Arterial uncontrolled hypertension, which is defined as a systolic arterial pressure value > 150 mmHg or diastolic arterial pressure value > 90 mmHg, despite adequate medical treatment.
  • Patients with a primary cancer diagnosis different from RCC, except in situ cervical carcinoma, baseline cellular carcinomas or superficial bladder tumours, prostate cancer pT1 gleason < 6 or other malign tumours which have received curative treatment > 5 years previous to the inclusion in this study.
  • Cardiac arrhythmia antecedents, that require treatment with anti-arrhythmics (except for beta-blockers or digoxin), symptomatic coronary disease or ischemia (myocardial infarction in the previous 6 months) or congestive cardiac insufficiency > New York Heart Association (NYHA) class II
  • Patients with active bacterial or fungal infectious processes, which are considered severe from the clinical point of view (≥ Common Terminology Criteria from the National Cancer Institute [CTC from NCI] grade 2, version 3)
  • Patients that present previously known positive serology for HIV or chronic hepatitis B or C.
  • Antecedents of organ allograft.
  • Meningeal carcinomatosis or symptomatic uncontrolled cerebral disease.
  • Patients with epileptic disorders that require medication (such as antiepileptics).
  • All unstable conditions that could put the patient's security and/or his study accomplishment in danger.
  • Abuse of substances, clinical conditions, psychological or social, that may interfere with the patient's participation in the study or with the evaluation of the study's results.
  • Patients that present any contraindication or allergy to the study's investigational product.
  • Patients that are participating or that have participated in any clinical trial in the 4 weeks previous to inclusion.
  • Pregnant or breastfeeding women. Women of fertile age must have a negative result in the pregnancy test performed 7 days before the beginning of the administration of the study medication. Both men and women included in the study must use an adequate contraceptive method.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Spain
 
NCT00496301
SOGUG-02-06
Yes
Dr. Bellmunt Molins, Spanish Oncology Genito-Urinary Group
Spanish Oncology Genito-Urinary Group
Not Provided
Study Chair: Joaquim Bellmunt Molins, MD SOGUG
Spanish Oncology Genito-Urinary Group
January 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP